Prognoz qilingan narxning foydaga nisbati: Neurocrine Biosciences Inc (NBIX)

Neurocrine Biosciences (NBIX) grafik logotipi

Neurocrine Biosciences (NBIX) o'sishi harakat buzilishlarini davolash vositalari savdosiga va yangi molekulalar ishlab chiqilishiga bog'liq. Fundamental muvaffaqiyat Ingrezza dominantligiga va FDA tasdiqlashlariga asoslangan. Ushbu GURU.Markets platformasi grafigidagi kompaniyaning prognoz qilingan P/E koeffitsiyenti 17.10 metrikaning bazaviy ko'rsatkichini aks ettiruvchi tendentsiyani namoyish etadi. Dori vositalarini ishlab chiqish AI yordamida tezlashmoqda, garchi yakuniy testlar hali ham shifokorlarning ishtirokini talab qilsa-da.

Kelajakdagi narx-foyda multiplikatori: Neurocrine Biosciences, Inc. (NBIX) 04.07.2022 - 18.11.2026 uchun

neurocrine.com (NBIX) kompaniyasi koʻrsatkichlari kesimi va tahlili

- kotirovkalar va tahlilchilar prognozi:
- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
Fundamental baholash:Neurocrine Corp
Neurocrine Biosciences brendining mahsuloti

Neurocrine Biosciences (NBIX) uchun ushbu ko'rsatkich aksiyalarning prognoz qilingan daromadlariga nisbatan adolatli qiymatini belgilaydi. Ushbu metrika aktivning haddan tashqari qimmat yoki arzonligini aniqlash uchun joriy narxni kutilayotgan yillik daromad bilan solishtiradi. Kompaniyaning forward P/E koeffitsiyentini tahlil qilish narx korreksiyasi xatarlarini baholash imkonini beradi. Past qiymatlar noelast talab va Ingrezza dominantligiga tayangan biznesning barqarorligini tasdiqlab, kompaniyaga investitsiyalarni yanada xavfsizroq qiladi.

Asosiy raqobatchilar

Forvard P/E multiplikatori BIIB|Regencell (RGC) - Forvard narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati axsome.com AXSM|Forvard P/E multiplikatori ACADIA Pharmaceuticals ACAD|XENE - Kelajakdagi narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Kelajakdagi narxning foydaga nisbati|CPRX (Catalyst Pharmaceuticals) - Kelajakdagi narxning foydaga nisbati|DNLI (denalitherapeutics.com) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati HRMY (Harmony Biosciences Holdings, Inc.)|Forvard P/E multiplikatori BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Narxning kutilayotgan foydaga nisbati|anavex.com - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori CBLL (CeriBell, Inc.)|PRTA: Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati ALEC|ANNX (Annexon Biosciences Inc.) - Forvard P/E multiplikatori|omeros.com - Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Neurogene (NGNE)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati AC Immune SA|Forvard P/E multiplikatori VYGR (voyagertherapeutics.com)|Forvard P/E multiplikatori Neumora NMRA|Scilex Holding - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Tevogen Bio Inc.|Alpha Cognition (ACOG) - Kelajakdagi narxning foydaga nisbati|cogrx.com (CGTX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Inhibikase Therapeutics|Cassava (SAVA) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Assertio Therapeutics (ASRT)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Coya|Vistagen - Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori OVID|Acumen Pharmaceuticals Inc. - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati CervoMed Inc|ATHE: Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Clene Nanomedicine|Kelajakdagi narxning foydaga nisbati PepGen Corp|Jupiter Neurosciences (JUNS) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Relmada Therapeutics, Inc. (RLMD)|ANVS - Prognoz qilingan narx-foyda nisbati|gracetx.com - Prognoz qilingan narxning foydaga nisbati|AIFF: Narxning kelajakdagi foydaga nisbati|Klotho Neurosciences - Forvard P/E multiplikatori|NRSN (NeuroSense Therapeutics Ltd.) - Narxning kelajakdagi foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|MTVA (MetaVia Inc.) - Kelajakdagi narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati NeurAxis, Inc|Kelajakdagi narxning foydaga nisbati HSDT|Forvard P/E multiplikatori PASG|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Athira ATHA|Addex Therapeutics - Forvard P/E multiplikatori|ALZN - Forvard P/E multiplikatori|Cyclerion (CYCN) - Kelajakdagi narxning foydaga nisbati|Protagenic (PTIX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea|Narxning kelajakdagi foydaga nisbati CRGT (Cortigent)|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori CARA (Cara Therapeutics Inc)|CHRO - Prognoz qilingan narxning foydaga nisbati|ELYM: Prognoz qilingan narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Kelajakdagi narxning foydaga nisbati|Marinus - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati NKGen Biotech Inc|NRBO: Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati SAGE (Sage Therapeutics, Inc.)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neurotrope|Kelajakdagi narxning foydaga nisbati Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Prognoz qilingan narx-foyda nisbati|WENA: Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori CERE (Cerevel Therapeutics)